Expertise in
13
conditions

Dr. Mateusz Opyrchal

Oncology
Indiana University Health West Hospital
1111 Ronald Reagan Pkwy, 
Avon, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
13
conditions
Indiana University Health West Hospital
1111 Ronald Reagan Pkwy, 
Avon, IN 

Overview

Mateusz Opyrchal is an Oncologist practicing medicine in Avon, Indiana.

Dr. Opyrchal is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Angiosarcoma, HER-2 Positive Breast Cancer, and Paget Disease of the Breast.

He is actively involved in clinical research, co-authoring 71 peer reviewed articles and participating in 12 clinical trials. Dr. Opyrchal is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Indiana University Health
Iu Health West Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 13 Less Insurance Carriers -

Locations

Indiana University Health West Hospital
1111 Ronald Reagan Pkwy, Avon, IN 46123
Other Locations
Indiana University Health University Hospital
550 University Blvd, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

TK IMPACT: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing: Physician Decision Impact Study
TK IMPACT: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing: Physician Decision Impact Study
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Other, Device
Study Phase: Not Applicable
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Enrollment Status: Terminated
Publish Date: July 09, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab
Study Phase: Phase 1/Phase 2
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2026
Intervention Type: Biological
Study Drugs: DC1 Vaccine, WOKVAC Vaccine
Study Phase: Phase 2
A Phase I Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA in Subjects With Solid Tumors
A Phase I Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA in Subjects With Solid Tumors
Enrollment Status: Terminated
Publish Date: April 13, 2025
Intervention Type: Combination product
Study Phase: Phase 1
A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 With Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer
A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 With Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer
Enrollment Status: Completed
Publish Date: August 13, 2024
Intervention Type: Drug
Study Drugs: Palbociclib, T-DM1
Study Phase: Phase 2
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drugs: LY3475070, Pembrolizumab
Study Phase: Phase 1
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug, Procedure, Biological
Study Drugs: Celecoxib, Recombinant Interferon Alfa-2b, Rintatolimod, Pembrolizumab
Study Phase: Early Phase 1
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Procedure, Drug, Genetic, Biological
Study Phase: Phase 2
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

71 Total Publications

Iron diminishes immunosuppressive macrophages and enhances anti-PD-1 immunotherapy in breast cancer models.
Iron diminishes immunosuppressive macrophages and enhances anti-PD-1 immunotherapy in breast cancer models.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 22, 2025
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (8.7 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lawrence Einhorn is an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Einhorn is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Mediastinal Tumor, and Orchiectomy. Dr. Einhorn is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (8.6 miles away)
317-944-0920
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nasser Hanna is an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Hanna is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Testicular Cancer, Teratoma of the Mediastinum, and Orchiectomy. Dr. Hanna is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (8.7 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathy Miller is an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Miller is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Salpingo-Oophorectomy. Dr. Miller is currently accepting new patients.

Frequently Asked Questions about Dr. Mateusz Opyrchal

How do I make an appointment with Dr. Mateusz Opyrchal?

You can book an appointment with Dr. Mateusz Opyrchal by calling their office at 317-274-8660. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mateusz Opyrchal a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mateusz Opyrchal is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mateusz Opyrchal specialize in?

While Dr. Mateusz Opyrchal is a Oncology, they have specific expertise in Breast Cancer, Angiosarcoma, and HER-2 Positive Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mateusz Opyrchal participate in research or clinical trials?

Yes. Dr. Mateusz Opyrchal has published 71 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Mateusz Opyrchal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mateusz Opyrchal accept my insurance?

Dr. Mateusz Opyrchal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-274-8660 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Opyrchal's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile